

## Freeform Search

Database:

US Pre-Grant Publication Full-Text Database  
 US Patents Full-Text Database  
 US OCR Full-Text Database  
 EPO Abstracts Database  
 JPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

Term:

L14 same l12

Display:  Documents in Display Format:  Starting with Number Generate: ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

Search

Clear

Interrupt

### Search History

DATE: Friday, July 16, 2004 [Printable Copy](#) [Create Case](#)

#### Set Name Query

side by side

#### Hit Count Set Name

result set

DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ

<u>L15</u>	L14 same l12	2	<u>L15</u>
<u>L14</u>	modi\$ or revers\$	3611935	<u>L14</u>
<u>L13</u>	L12 same l6	6	<u>L13</u>
<u>L12</u>	l9 with l1	21	<u>L12</u>
<u>L11</u>	l9 same l3	4	<u>L11</u>
<u>L10</u>	L9 with l3	3	<u>L10</u>
<u>L9</u>	surface potential or zeta potential	23015	<u>L9</u>
<u>L8</u>	L7 same l5	28	<u>L8</u>
<u>L7</u>	surface	7796737	<u>L7</u>
<u>L6</u>	polyanionic or anionic or negativ\$	1210811	<u>L6</u>
<u>L5</u>	L4 with l3	221	<u>L5</u>
<u>L4</u>	DNA or nucleic or plasmid	246149	<u>L4</u>
<u>L3</u>	L2 with l1	778	<u>L3</u>
<u>L2</u>	neutral\$	688451	<u>L2</u>
<u>L1</u>	cationic lipid or cationic amphiphile or cationic liposome	9388	<u>L1</u>

END OF SEARCH HISTORY

[First Hit](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L8: Entry 6 of 28

File: PGPB

Nov 14, 2002

DOCUMENT-IDENTIFIER: US 20020169138 A1

TITLE: Delivery vehicles for bioactive agents and uses thereof

Summary of Invention Paragraph:

[0006] Additionally, it is known that the transfection activity of cationic liposomes is interfered with by serum components which presumably neutralize the unpaired positive charges in the complexes which are essential for binding of DNA/lipid complexes to the cell surface. See, e.g., Felgner, P. L. et al. Nature 337:387-388, 1989; Felgner, P. L., et al. Proc. Natl. Acad. Sci. USA 84:7413-7417, 1987; and Gao, X. and Huang, L., Biochem. Biophys. Res. Comm. 179:280-285, 1991. Because of this problem alone, the use of cationic liposomes for gene transfer is limited to the situation where a minimal amount of serum is present; accordingly, cationic liposomes as an in vivo delivery system are of limited value.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L11: Entry 2 of 4

File: PGPB

Mar 21, 2002

DOCUMENT-IDENTIFIER: US 20020034537 A1

TITLE: Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites

Summary of Invention Paragraph:

[0018] This McDonald et al. patent describes the use of cationic liposomes that may include both neutral and cationic lipids, for example, having 5 mol % or more of cationic lipids or, specifically, having neutral lipids in an amount of about 45% and cationic lipids in an amount of about 55%. While McDonald et al. indicates that cationic liposomes have a zeta potential of greater than 0 mV, this patent does not teach any specific zeta potential or isoelectric point, or ranges thereof, as being preferred for the selective targeting of angiogenic endothelial cells. McDonald et al. also does not indicate the preferred upper limit of cationic lipid to use in the cationic liposome composition for selective targeting of angiogenic endothelial cells. 100161 Thurston et al. (1998) also describes the targeting of endothelial cells in tumors and chronic inflammation in mice using cationic liposomes. Thurston uses cationic liposomes having 55 mol % of cationic component. Thurston does not disclose the specific zeta potential or isoelectric point or ranges thereof for selective targeting of endothelial cells in tumors or chronic inflammation in mice.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)